THYROID GLAND ANAPLASTIC CARCINOMA
Clinical trials for THYROID GLAND ANAPLASTIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new THYROID GLAND ANAPLASTIC CARCINOMA trials appear
Sign up with your email to follow new studies for THYROID GLAND ANAPLASTIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise against deadly thyroid cancer before surgery
Disease control OngoingThis study tests whether giving three drugs (pembrolizumab, dabrafenib, and trametinib) before surgery can help control a rare and aggressive thyroid cancer called anaplastic thyroid cancer that has a specific gene change (BRAF V600E). The goal is to make surgery more successful …
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:39 UTC
-
New drug shrinks thyroid tumors before surgery in early trial
Disease control OngoingThis study tests whether giving the drug selpercatinib before surgery can shrink thyroid cancers that have a specific genetic change (RET alteration). About 30 people with advanced or recurrent thyroid cancer will receive the drug and then have surgery. The goal is to see if the …
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:28 UTC
-
Personalized cell therapy takes on resistant cancers
Disease control OngoingThis study tests a treatment made from a patient's own immune cells (called LN-145) for cancers like ovarian, triple-negative breast, anaplastic thyroid, and bone sarcomas that have not responded to standard therapy or have returned. The cells are taken from the tumor, grown in a…
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:26 UTC
-
Promising combo therapy targets deadly thyroid cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with aggressive thyroid cancers (anaplastic or poorly differentiated) live longer. About 50 adults with advanced or inoperable cancer will receive different drug combinati…
Matched conditions: THYROID GLAND ANAPLASTIC CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC